Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED Phase 1

Optimization of Smoking Cessation Strategies Concurrent With Treatment of Tobacco Related Malignancies

NCT02048917 · View on ClinicalTrials.gov ↗

Study Summary

The purpose of this study is to find an optimal smoking cessation strategy in patients undergoing therapy for lung and head and neck cancers at selected cancer centers in Kentucky by delivering high quality smoking cessation to all enrolled patients. This study will also examine the feasibility of routinely implementing an array of smoking cessation strategies for this patient population.

Interventions

  • DRUG High Intensity Counseling + Long Acting NRT + PRN NRT
  • DRUG High Intensity Counseling + bupropion + PRN NRT
  • DRUG High Intensity Counseling + varenicline + PRN NRT
  • DRUG High Intensity Counseling + Long Acting NRT
  • DRUG High Intensity Counseling + bupropion

Study Locations (10)

Kentucky

  • King's Daughters Medical Center — Ashland
  • Hardin Memorial Health Cancer Care Center — Elizabethtown
  • ARH Cancer Center — Hazard
  • Kentucky Cancer Clinic — Hazard
  • Lexington Veterans Affair Medical Center — Lexington
  • University Of Kentucky, Markey Cancer Center — Lexington
  • University of Louisville, James Graham Brown Cancer Center — Louisville
  • St. Claire Regional Medical Center — Morehead
  • Owensboro Health — Owensboro

West Virginia

  • St. Mary's Medical Center — Huntington

Trial Details

FieldValue
Enrollment Target 93 participants
Start Date 2014-07-22
Est. Completion 2019-05-15
Phase Phase 1

Sponsor

University of Kentucky

47 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02048917

The ClinicalTrials.gov registry entry for NCT02048917 describes a study currently listed as completed. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 93 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Kentucky, which has 47 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with Lung Cancer appearing as the primary indexed condition, and to 5 interventions — of which High Intensity Counseling + Long Acting NRT + PRN NRT is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT02048917 reports 10 study locations spanning 2 distinct geographic areas — top geographies include Kentucky, West Virginia. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT02048917 about?

NCT02048917 is a clinical study titled "Optimization of Smoking Cessation Strategies Concurrent With Treatment of Tobacco Related Malignancies". The purpose of this study is to find an optimal smoking cessation strategy in patients undergoing therapy for lung and head and neck cancers at selected cancer centers in Kentucky by delivering high quality smoking cessation to all enrolled patients. This study will also examine the feasibility of r...

What is the current status of trial NCT02048917?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 93 participants. The study started on 2014-07-22. Estimated completion is 2019-05-15.

What conditions does trial NCT02048917 study?

This clinical trial studies the following conditions: Lung Cancer, Head and Neck Cancer. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT02048917?

The interventions under investigation include: High Intensity Counseling + Long Acting NRT + PRN NRT (DRUG), High Intensity Counseling + bupropion + PRN NRT (DRUG), High Intensity Counseling + varenicline + PRN NRT (DRUG), High Intensity Counseling + Long Acting NRT (DRUG), High Intensity Counseling + bupropion (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT02048917?

This trial is sponsored by University of Kentucky, which has 47 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT02048917 being conducted?

This trial has 10 study locations across Kentucky, West Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial